mentioned in article last week, follow up rumors this week. their hypertension program and new cardio drugs look like a fit - they have a unique product development and salesforce model, and do a lot of licensing and partnerships. may not be straight BO
This is a rumor on stocktwits and is apparently gaining traction after Forest mentioned with AMRN in article last week...anyone on this board that follows Forest know anything about this?
Called exactly what would happen on the CC...scripts upside, revs in-line with consensus, positive view moving forward on Anchor, no impact from Italian study on Vascepa, all analyst seem to agree this AM.
So does SR and he's the only one writing articles that have substance.
Fair enough, but Leerink and Aegis came out with reports today, reiterating ratings and citing both script growth, supply exclusivity and NCE progress. Both maintained likleyhood of near-term partner/acquisition scenario.
Let's see, SR said scripts would go as expected, and they are (see Leerink report today). He said AMRN would get NCE and now we see the FDA release an updated MAPP designating Vascepa different than Lovaza. He confirmed all the supply partners well before company releases and they have all come true. Interesting to see the shorts vanish their bashing of AMRN and SR when the stock reverses. I don't follow everything he says and I would not bet my $ on his timing predictions, but all key events have come to fruition.
Guess you didnt see the FDA updated MAPP guidance documentation. SR's NCE call looks like it will come true soon enough.
He remains consistent with his original assertion that it will be taken out due to Anchor being approved. $25 looks high from here, but so did $19 when we were back in the single digits. Comparing SR with AF is ridiculous though. SR also does not receive any compensation for his articles, even from Seeking Alpha. He has been right on all major news events surrounding Amarin, even though stock price has not reacted. \AF is nothing more than a paid pumper/dumper for the Street with no truth to his articles.